ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Dana-Farber Cancer Institute at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Dana-Farber Cancer Institute takes part in 48 sessions at ESMO 2026 in Madrid. Its program spans breast cancer treatment, immunotherapy and biomarkers. Topics include personalized cancer vaccines and using blood-based DNA profiling to track treatment resistance in prostate and pancreatic cancers.
| Organization | ESMO 2026 Attendance |
|---|---|
Dana-Farber Cancer Institute Boston, MA | |
Cancer treatment and research institute in Boston, Massachusetts, and a teaching affiliate of Harvard Medical School. | Satellite Fri Oct 23 10:15–10:40 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Higher GCN2 expression is associated with favorable clinical and genomic features in advanced prostate cancer Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Treatment outcomes after platinum, taxane, and pembrolizumab (KEYNOTE-B10 Regimen) for 1st-line advanced head and neck squamous cell carcinoma (HNSCC) Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Tumor mutational profiles and clinical predictors in late recurrence (>5 years) of skin-limited melanoma Melanoma & skin cancersBiomarkers & precision oncology Talk Fri Oct 23 14:10–14:30 Personalising vaccines using peptides, DNA, mRNA and more Melanoma & skin cancers Poster Fri Oct 23 15:15–16:00 Baseline and dynamic changes in circulating tumor (ct) DNA as correlates of intrinsic and acquired resistance to 177Lu-PSMA-617 (LuPSMA) in metastatic castration-resistant prostate cancer (mCRPC) Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Cell-free chromatin epigenomic profiling enables non-invasive subtyping of pancreatic cancer Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Characterizing the long tail of somatic mutations in clear-cell renal cell carcinoma (ccRCC) Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Clinical and transcriptomic correlates of primary resistance to nivolumab plus ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC) Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Comprehensive plasma epigenomic profiling derived lineage states in mCRPC associate with 177Lu-PSMA-617 response and resistance Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Decoding tumor gene expression from circulating chromatin at single-gene resolution Gastrointestinal cancersGenitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Functional epigenomic liquid biopsy to guide treatment at EV/P resistance in metastatic urothelial carcinoma (mUC): Emerging role of ERBB3 Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Wearable derived physical activity and patient-reported fatigue and sleep differ by hot flash severity levels during the initial treatment phase in the LIBERTAS trial Genitourinary cancersNursing & supportive care Talk Fri Oct 23 15:35–15:55 Chair Fri Oct 23 16:15–17:00 The best is yet to come: Immune modulating approaches in neuro- oncology Sarcoma, CNS, head & neck and rare cancers Satellite Fri Oct 23 18:20–18:30 Resectable NSCLC: Personalized treatment selection and patient support to optimize outcomes Lung & thoracic cancersBiomarkers & precision oncology Satellite Fri Oct 23 19:15–19:30 From breakthrough to backbone: The evolving role of immunotherapy across stages of Lung & thoracic cancersBiomarkers & precision oncology Chair Sat Oct 24 08:30–10:00 Rapid oral 1: NSCLC, metastatic Lung & thoracic cancers Abstract Sat Oct 24 08:50–09:00 Abstract Sat Oct 24 09:10–09:22 Invited Discussant LBA74 and 2636RO Lung & thoracic cancers Abstract Sat Oct 24 10:20–10:25 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Clinical and molecular characteristics of leptomeningeal disease in metastatic breast cancer patients: A prospective observational registry study Breast cancerSarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 Expert consensus on management of ribociclib (RIB)-associated liver-related adverse events (AEs) in HR+/HER2− breast cancer: A modified Delphi panel Breast cancerNursing & supportive care Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Satellite Sat Oct 24 13:20–13:40 Recent Updates in Resectable LA HNSCC Sarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 13:40–14:10 MDT Case Discussion Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 17:18–17:30 LBA3 - Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers Satellite Sat Oct 24 18:40–18:55 Satellite Sat Oct 24 18:55–19:05 Interactive panel discussion Breast cancer Satellite Sat Oct 24 19:20–19:30 Interactive panel discussion Breast cancer Satellite Sat Oct 24 19:40–19:50 Interactive panel discussion Breast cancer Abstract Sun Oct 25 08:30–08:40 Talk Sun Oct 25 08:45–09:00 Chair Sun Oct 25 10:15–11:45 Talk Sun Oct 25 10:15–10:35 Abstract Sun Oct 25 10:35–10:45 Invited Discussant 690O and 691O Sarcoma, CNS, head & neck and rare cancers Abstract Sun Oct 25 10:35–10:47 Invited Discussant LBA29 and LBA30 Gastrointestinal cancers Talk Sun Oct 25 11:15–11:30 Satellite Sun Oct 25 13:35–13:55 Deep Dive: The Pivotal Evidence Base in nmCRPC Genitourinary cancers Satellite Sun Oct 25 13:45–14:05 Satellite Sun Oct 25 13:55–14:25 Abstract Sun Oct 25 14:45–14:50 Talk Sun Oct 25 15:15–16:00 Abstract Sun Oct 25 15:39–15:44 Satellite Sun Oct 25 18:38–19:33 Satellite Sun Oct 25 18:40–19:10 ADC Biomarkers and their Current Role in Patients with NSCLC with Actionable Genomic Lung & thoracic cancersBiomarkers & precision oncology Satellite Sun Oct 25 19:33–19:48 Satellite Sun Oct 25 19:48–19:58 Ask the Expert: Panel Discussion and Audience Q&A Breast cancer Talk Mon Oct 26 10:15–10:35 Presentation by Expert Genitourinary cancers Chair Mon Oct 26 10:30–11:15 Abstract Mon Oct 26 10:50–10:55 Abstract Mon Oct 26 11:27–11:32 Poster Mon Oct 26 12:00–12:45 Biomarkers associated with response to the CAR-T cell therapy LB2102 in subjects with SCLC or LCNEC Lung & thoracic cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 RGT-61159, an oral MYB splicing modulator, demonstrates exposure-dependent target engagement and early clinical activity in advanced adenoid cystic carcinoma Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 17:30–17:42 Invited Discussant LBA11 Gynaecological cancersSarcoma, CNS, head & neck and rare cancers |
Find decision makers at Dana-Farber Cancer Institute
Tell us what you sell and we’ll find the people at Dana-Farber Cancer Institute most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction